Basic and clinical studies on NM441 in respiratory infection

Michihiro Gaja, Hiroshi Fukuhara, Jun Inadome, Yukino Hisagai, Mitsuyuki Aragaki, Atsushi Saito, Nobuchika Kusano, Masao Tateyama, Hajime Uema

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We performed basic and clinical studies on a new quinolone antibiotic, NM441, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MICs) of NM394, an active form of NM441, against a total of 362 clinical isolated strains of 13 species were measured and compared with those of other 4 drugs (ofloxacin, ciprofloxacin, tosufloxacin and sparfloxacin). 2) Concentrations in serum and sputum: NM441 was administered to 1 patient with pneumonia at a dose of 200mg once, and the serum and sputum concentrations of NM394 were measured by HPLC method. The maximum serum concentration was 0.61μg/ml at 2h and 4h after administration, and the maximum sputum concentration was 1.21μg/ml at 4~6h after administration. These results suggested the favorable penetration of NM441 into lungs. 3) Clinical study results: NM441 was administered to 16 patients with respiratory infections, and its clinical efficacy, bacteriological efficacy and side effects were investigated. Clinical response was excellent in 3 cases, good in 12 and poor in 1, and the efficacy rate was 93.8%, showing a favorable response. As for side effects and abnormal laboratory findings, eruption in 1 case, nausea in 1 and increase of eosinophil in 1 were observed. However, all of these cases improved immediately after termination of NM441 treatment, and the safety of NM441 was confirmed.

Original languageEnglish
Pages (from-to)356-361
Number of pages6
JournalJapanese Journal of Chemotherapy
Volume44
Issue numberSUPPL. 1
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Respiratory Tract Infections
Sputum
tosufloxacin
Serum
Ofloxacin
Quinolones
Microbial Sensitivity Tests
Ciprofloxacin
prulifloxacin
Clinical Studies
Eosinophils
Nausea
Pneumonia
High Pressure Liquid Chromatography
Anti-Bacterial Agents
Safety
Lung
Pharmaceutical Preparations

Keywords

  • NM441

ASJC Scopus subject areas

  • Pharmacology

Cite this

Gaja, M., Fukuhara, H., Inadome, J., Hisagai, Y., Aragaki, M., Saito, A., ... Uema, H. (1996). Basic and clinical studies on NM441 in respiratory infection. Japanese Journal of Chemotherapy, 44(SUPPL. 1), 356-361.

Basic and clinical studies on NM441 in respiratory infection. / Gaja, Michihiro; Fukuhara, Hiroshi; Inadome, Jun; Hisagai, Yukino; Aragaki, Mitsuyuki; Saito, Atsushi; Kusano, Nobuchika; Tateyama, Masao; Uema, Hajime.

In: Japanese Journal of Chemotherapy, Vol. 44, No. SUPPL. 1, 1996, p. 356-361.

Research output: Contribution to journalArticle

Gaja, M, Fukuhara, H, Inadome, J, Hisagai, Y, Aragaki, M, Saito, A, Kusano, N, Tateyama, M & Uema, H 1996, 'Basic and clinical studies on NM441 in respiratory infection', Japanese Journal of Chemotherapy, vol. 44, no. SUPPL. 1, pp. 356-361.
Gaja M, Fukuhara H, Inadome J, Hisagai Y, Aragaki M, Saito A et al. Basic and clinical studies on NM441 in respiratory infection. Japanese Journal of Chemotherapy. 1996;44(SUPPL. 1):356-361.
Gaja, Michihiro ; Fukuhara, Hiroshi ; Inadome, Jun ; Hisagai, Yukino ; Aragaki, Mitsuyuki ; Saito, Atsushi ; Kusano, Nobuchika ; Tateyama, Masao ; Uema, Hajime. / Basic and clinical studies on NM441 in respiratory infection. In: Japanese Journal of Chemotherapy. 1996 ; Vol. 44, No. SUPPL. 1. pp. 356-361.
@article{7a18982e82a442999fdd2b7e9e6c2bdd,
title = "Basic and clinical studies on NM441 in respiratory infection",
abstract = "We performed basic and clinical studies on a new quinolone antibiotic, NM441, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MICs) of NM394, an active form of NM441, against a total of 362 clinical isolated strains of 13 species were measured and compared with those of other 4 drugs (ofloxacin, ciprofloxacin, tosufloxacin and sparfloxacin). 2) Concentrations in serum and sputum: NM441 was administered to 1 patient with pneumonia at a dose of 200mg once, and the serum and sputum concentrations of NM394 were measured by HPLC method. The maximum serum concentration was 0.61μg/ml at 2h and 4h after administration, and the maximum sputum concentration was 1.21μg/ml at 4~6h after administration. These results suggested the favorable penetration of NM441 into lungs. 3) Clinical study results: NM441 was administered to 16 patients with respiratory infections, and its clinical efficacy, bacteriological efficacy and side effects were investigated. Clinical response was excellent in 3 cases, good in 12 and poor in 1, and the efficacy rate was 93.8{\%}, showing a favorable response. As for side effects and abnormal laboratory findings, eruption in 1 case, nausea in 1 and increase of eosinophil in 1 were observed. However, all of these cases improved immediately after termination of NM441 treatment, and the safety of NM441 was confirmed.",
keywords = "NM441",
author = "Michihiro Gaja and Hiroshi Fukuhara and Jun Inadome and Yukino Hisagai and Mitsuyuki Aragaki and Atsushi Saito and Nobuchika Kusano and Masao Tateyama and Hajime Uema",
year = "1996",
language = "English",
volume = "44",
pages = "356--361",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Basic and clinical studies on NM441 in respiratory infection

AU - Gaja, Michihiro

AU - Fukuhara, Hiroshi

AU - Inadome, Jun

AU - Hisagai, Yukino

AU - Aragaki, Mitsuyuki

AU - Saito, Atsushi

AU - Kusano, Nobuchika

AU - Tateyama, Masao

AU - Uema, Hajime

PY - 1996

Y1 - 1996

N2 - We performed basic and clinical studies on a new quinolone antibiotic, NM441, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MICs) of NM394, an active form of NM441, against a total of 362 clinical isolated strains of 13 species were measured and compared with those of other 4 drugs (ofloxacin, ciprofloxacin, tosufloxacin and sparfloxacin). 2) Concentrations in serum and sputum: NM441 was administered to 1 patient with pneumonia at a dose of 200mg once, and the serum and sputum concentrations of NM394 were measured by HPLC method. The maximum serum concentration was 0.61μg/ml at 2h and 4h after administration, and the maximum sputum concentration was 1.21μg/ml at 4~6h after administration. These results suggested the favorable penetration of NM441 into lungs. 3) Clinical study results: NM441 was administered to 16 patients with respiratory infections, and its clinical efficacy, bacteriological efficacy and side effects were investigated. Clinical response was excellent in 3 cases, good in 12 and poor in 1, and the efficacy rate was 93.8%, showing a favorable response. As for side effects and abnormal laboratory findings, eruption in 1 case, nausea in 1 and increase of eosinophil in 1 were observed. However, all of these cases improved immediately after termination of NM441 treatment, and the safety of NM441 was confirmed.

AB - We performed basic and clinical studies on a new quinolone antibiotic, NM441, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MICs) of NM394, an active form of NM441, against a total of 362 clinical isolated strains of 13 species were measured and compared with those of other 4 drugs (ofloxacin, ciprofloxacin, tosufloxacin and sparfloxacin). 2) Concentrations in serum and sputum: NM441 was administered to 1 patient with pneumonia at a dose of 200mg once, and the serum and sputum concentrations of NM394 were measured by HPLC method. The maximum serum concentration was 0.61μg/ml at 2h and 4h after administration, and the maximum sputum concentration was 1.21μg/ml at 4~6h after administration. These results suggested the favorable penetration of NM441 into lungs. 3) Clinical study results: NM441 was administered to 16 patients with respiratory infections, and its clinical efficacy, bacteriological efficacy and side effects were investigated. Clinical response was excellent in 3 cases, good in 12 and poor in 1, and the efficacy rate was 93.8%, showing a favorable response. As for side effects and abnormal laboratory findings, eruption in 1 case, nausea in 1 and increase of eosinophil in 1 were observed. However, all of these cases improved immediately after termination of NM441 treatment, and the safety of NM441 was confirmed.

KW - NM441

UR - http://www.scopus.com/inward/record.url?scp=0029929336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029929336&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029929336

VL - 44

SP - 356

EP - 361

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -